<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Serge Louis Boulet et al. Group Art Unit: 1626

Serial No.: 10/597,835 Sun Jae Y Loewe

Application Date: February 18, 2005 Conf No.; 6937

US Nat'l Entry

Date (if applicable): August 9, 2006

For: PHARMACEUTICAL COMPOUNDS

Docket No.: X-16288

STATEMENT UNDER 37 CFR 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit the following statement under §1.97(e):

I, Mark A. Winter, hereby state that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Applicants request consideration of this information.

Respectfully submitted, /Mark A. Winter/

Mark A. Winter Agent for Applicants Registration No. 53,782 Phone: 317-276-5362

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288 September 11, 2008